New drug superior to tamoxifen in blocking return of breast cancer

12/10/2004 | Wall Street Journal, The

AstraZeneca's Arimidex has shown in trials it does a much better job of preventing the recurrence of breast cancer than the popular tamoxifen, according to a study in the journal Lancet. The study, funded by AstraZeneca, said Arimidex could defend against up to 80% of the most common types of tumors that occur after menopause, compared with a 50% rate attributed to tamoxifen.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC